Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety

Randomised, quadruple-blind, parallel-group Phase II pilot of LSD-assisted psychotherapy in people with advanced potentially fatal illness and clinically significant anxiety; participants receive two day-long dosing psychotherapy sessions 2–4 weeks apart with either 200 µg or 20 µg LSD.

Primary outcomes assess anxiety and quality of life at acute and follow-up visits; participants who receive the active placebo in the randomised phase may opt into an open-label phase receiving the full dose.